文献速递物质与行为成瘾精神分裂症与精神病性障碍心境障碍

跨诊断与障碍水平全基因组关联研究提升非洲与欧洲血统物质使用及精神疾病遗传风险图谱精度

Transdiagnostic and Disorder-Level Genome-Wide Association Studies Enhance Precision of Substance Use and Psychiatric Genetic Risk Profiles in African and European Ancestries.
PubMed 文献 · Biol Psychiatry · 2025-05-08

该研究应用基因组结构方程模型,利用欧洲和非洲血统个体的全基因组关联研究汇总统计量,剖析物质使用障碍与精神病性、心境及焦虑障碍的共同与独立遗传结构。欧洲血统中跨诊断遗传因子分别代表物质使用障碍、精神病性障碍和心境/焦虑障碍,并发现2个新先导SNP;非洲血统中遗传因子代表物质使用障碍和精神障碍,发现1个新先导SNP。遗传相关与PheWAS揭示共同与独立遗传因子与精神、社会人口学及医学表型的差异关联。

要点

  • 跨诊断与障碍水平遗传方法可提升共病理解与遗传发现特异性。
  • 欧洲血统中鉴定出心境因子2个新先导SNP,非洲血统中鉴定出物质使用因子1个新先导SNP。
  • 共同与独立遗传因子对精神、社会人口学及医学表型呈差异关联。

核心结论

  • 结合跨诊断与障碍水平遗传方法能增进对共病状况的理解并提高遗传发现特异性,有助于识别更有效的预防和治疗策略。

研究设计与样本

  • 应用基因组结构方程模型分析欧洲血统与非洲血统个体中物质使用障碍及精神病性、心境、焦虑障碍的全基因组关联研究汇总统计量。
  • 使用FUMA、遗传相关分析和全表型关联研究(PheWAS)表征生物学与表型关联。

主要发现

  • 在欧洲血统个体中,跨诊断遗传因子分别代表物质使用障碍、精神病性障碍和心境/焦虑障碍,全基因组关联研究鉴定出心境因子2个新先导单核苷酸多态性(SNP)。
  • 在非洲血统个体中,遗传因子代表物质使用障碍和精神障碍,全基因组关联研究鉴定出物质使用障碍因子1个新先导SNP。
  • 在欧洲血统个体中,二阶因子模型显示与广泛躯体和心理健康特征存在表型和基因型关联。
  • 遗传相关和PheWAS突显物质使用障碍与精神病性障碍的共同及独立遗传因子与精神、社会人口学和医学表型的差异关联。

临床怎么用

  • 在精神心理科临床中,可关注跨诊断与障碍水平遗传风险对共病评估的潜在价值,但需结合非遗传因素综合判断。
  • 遗传发现的特异性提升可能为未来精准预防和治疗策略提供线索,当前尚不能直接用于临床决策。

局限性

  • 研究基于全基因组关联研究汇总统计量,未涉及个体层面遗传与环境交互验证。
  • 非欧洲血统群体(非洲血统)的遗传发现仍需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Substance use disorders (SUDs) and psychiatric disorders frequently co-occur, and their etiology likely reflects both transdiagnostic (i.e., common/shared) and disorder-level (i.e., independent/nonshared) genetic influences. Understanding the genetic influences that are shared and those that operate independently of the shared risk could enhance precision in diagnosis, prevention, and treatment, but this remains underexplored, particularly in non-European ancestry groups. METHODS: We applied genomic structural equation modeling to examine the common and independent genetic architecture among SUDs and psychotic, mood, and anxiety disorders using summary statistics from genome-wide association studies (GWASs) conducted in European ancestry (EUR) and African ancestry (AFR) individuals. To characterize the biological and phenotypic associations, we used FUMA, conducted genetic correlations, and performed phenome-wide association studies (PheWASs). RESULTS: In EUR individuals, transdiagnostic genetic factors represented SUDs, psychotic disorders, and mood/anxiety disorders, with a GWAS identifying 2 novel lead single nucleotide polymorphisms (SNPs) for the mood factor. In AFR individuals, genetic factors represented SUDs and psychiatric disorders, and a GWAS identified 1 novel lead SNP for the SUD factor. In EUR individuals, second-order factor models showed phenotypic and genotypic associations with a broad range of physical and mental health traits. Finally, genetic correlations and PheWASs highlighted how common and independent genetic factors for SUDs and psychotic disorders were differentially associated with psychiatric, sociodemographic, and medical phenotypes. CONCLUSIONS: Combining transdiagnostic and disorder-level genetic approaches can improve our understanding of co-occurring conditions and increase the specificity of genetic discovery, which is critical for identifying more effective prevention and treatment strategies to reduce the burden of these disorders.

来源:Biol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Khan Y, Davis CN, Jinwala Z, et al. Transdiagnostic and Disorder-Level Genome-Wide Association Studies Enhance Precision of Substance Use and Psychiatric Genetic Risk Profiles in African and European Ancestries. Biol Psychiatry. 2025. PMID: 40345609. doi:10.1016/j.biopsych.2025.04.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。